Phase 1 expansion results of IDE397, a first-in-class, oral, MAT2A inhibitor (MAT2Ai) in MTAP deleted(del) non-small cell lung cancer (NSCLC) and urothelial cancer (UC)

被引：0
|
作者：
Herzberg, B. [1 ]
Johnson, M. [2 ]
Kim, C. G. [3 ]
Tolcher, A. [4 ]
Rodon, J. [5 ]
Mantia, C. [6 ]
Liu, J. [7 ]
Tripathi, A. [8 ]
Rodriguez, L. Paz-Ares [9 ]
Rouge, T. De la Motte [10 ]
Choi, C. M. [11 ]
Han, J. Y. [12 ]
Kwei, L. [13 ]
Liu, E. [14 ]
Sachdev, J. [14 ]
O'Quigley, M. [14 ]
White, M. [15 ]
Beaupre, D. [16 ]
Kim, H. R. [17 ]
机构：
[1] Columbia Univ, Dept Hematol & Oncol, Herbert Irving Comprehens Canc Ctr, New York, NY USA
[2] Sarah Cannon Res Inst, SCRI Dev Innovat Div, Nashville, TN USA
[3] Yonsei Canc Ctr, Dept Internal Med, Div Med Oncol, Seoul, South Korea
[4] NEXT Oncol, Clin Res, San Antonio, TX USA
[5] MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Div Canc Med, Houston, TX USA
[6] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Ctr Canc Therapeut Innovat, Dept Med Oncol, Boston, MA USA
[7] St Vincents Hosp Sydney, Med Oncol, Kinghorn Canc Ctr, Darlinghurst, NSW, Australia
[8] City Hope Comprehens Canc Ctr, Dept Med Oncol & Therapeut Res, Duarte, CA USA
[9] Hosp Univ 12 Octubre, Dept Med Oncol, Madrid, Spain
[10] Ctr Eugene Marquis, Dept Med Oncol, Rennes, France
[11] Univ Ulsan, Dept Oncol, Asan Med Ctr, Coll Med, Seoul, South Korea
[12] Natl Canc Ctr, Ctr Lung Canc, Goyang, South Korea
[13] IDEAYA Biosci, Biometr, San Francisco, CA USA
[14] IDEAYA Biosci, Clin Dev, San Francisco, CA USA
[15] IDEAYA Biosci, Res, San Francisco, CA USA
[16] IDEAYA Biosci, Clin Dev, San Diego, CA USA
[17] Yonsei Univ, Yonsei Canc Ctr, Div Med Oncol, Dept Internal Med,Coll Med, Seoul, South Korea
来源：
EUROPEAN JOURNAL OF CANCER | 2024年 / 211卷
关键词：
D O I：
10.1016/j.ejca.2024.114979
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
501LBA
引用
收藏
页码：S176 / S177
页数：2
相关论文
共 50 条
  • [41] MLN8237 (ALISERTIB), AN INVESTIGATIONAL AURORA A KINASE INHIBITOR, IN PATIENTS (PTS) WITH NON-SMALL CELL LUNG CANCER (NSCLC), SMALL CELL LUNG CANCER (SCLC), BREAST CANCER (BRC), HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC), AND GASTROESOPHAGEAL CANCER (GE): EMERGING PHASE (PH) 2 RESULTS
    Melichar, B.
    Lee, P.
    Alvarez, R. H.
    Degardin, M.
    Bennouna, J.
    Schusterbauer, C.
    Zhang, B.
    Benaim, E.
    Rosen, P.
    ANNALS OF ONCOLOGY, 2012, 23 : 160 - 160
  • [42] Phase (ph) 2 study of bortezomib ± docetaxel in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC):: Preliminary results.
    Fanucchi, MP
    Belt, RJ
    Fossella, FV
    Natale, RB
    Robert, F
    Fidias, P
    Kelly, K
    Kashala, O
    Shenkein, DP
    Schiller, JH
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 643S - 643S
  • [43] Results of a phase 2 study of STA-4783 in combination with paclitaxel and carboplatin in patients with previously untreated advanced non-small cell lung cancer (NSCLC)
    Hainsworth, J
    Weber, R
    Jacobs, M
    Fehrenbacher, L
    Schwartzberg, L
    Kalman, L
    Mills, G
    Dooley, W
    McLeod, M
    Dahl, TA
    Sherman, MS
    Salgia, R
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9059S - 9059S
  • [44] Brigatinib (BRG) in patients (Pts) with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in a phase 1/2 trial
    Bazhenova, L.
    Gettinger, S.
    Langer, C.
    Salgia, R.
    Gold, K.
    Rosell, R.
    Shaw, A.
    Weiss, G.
    Haney, J.
    Rivera, V.
    Haluska, F.
    Kerstein, D.
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2016, 27
  • [45] Brigatinib (BRG) in patients (pts) with ALK plus non-small cell lung cancer (NSCLC): Updates from a phase 1/2 trial.
    Bazhenova, Lyudmila
    Gettinger, Scott N.
    Langer, Corey J.
    Salgia, Ravi
    Gold, Kathryn A.
    Rosell, Rafael
    Shaw, Alice Tsang
    Weiss, Glen J.
    Haney, Jeff
    Rivera, Victor M.
    Kerstein, David
    Camidge, D. Ross
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [46] Biweekly docetaxel as first-line therapy in patients with advanced non-small cell lung cancer (NSCLC) and performance status (PS) 2: A phase II study of the Galician Lung Cancer Group
    Vazquez-Estevez, S.
    Leon, L.
    Firvida, J. L.
    Grande, C.
    Vazquez, F.
    Salgado, M.
    Casal, J.
    Baron, F. J.
    Abal, J.
    Garcia, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [47] TG01, a new potent COX-2 inhibitor in combination with erlotinib in metastatic or recurrent non-small cell lung cancer (NSCLC) patients: A phase 1 study
    Reckamp, K. L.
    Patel, R.
    Chen, L.
    Gitlitz, B. J.
    Davies, A. M.
    Jezior, D.
    Zaknoen, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [48] Phase 2 Multicenter Trial of ICOS agonist vopratelimab and a CTLA-4 inhibitor in PD-1/PD-L1 inhibitor experienced adult subjects with Non-small Cell Lung Cancer or Urothelial Cancer (EMERGE)
    Pachynski, Russell
    Govindan, Ramaswamy
    Hooper, Ellen
    Harvey, Christopher
    Hanson, Amanda
    Lacey, Sean
    McComb, Rachel
    Hart, Courtney
    Laken, Haley
    Baeck, Johan
    Trehu, Elizabeth
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [49] AZD9291, a mutant-selective EGFR inhibitor, as first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): Results from a phase 1 expansion cohort.
    Ramalingam, Suresh S.
    Yang, James Chih-Hsin
    Lee, Chee Khoon
    Kurata, Takayasu
    Kim, Dong-Wan
    John, Thomas
    Nogami, Naoyuki
    Ohe, Yuichiro
    Rukazenkov, Yuri
    Frewer, Paul
    Cantarini, Mireille
    Ghiorghiu, Serban
    Janne, Pasi A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [50] TIME, a Phase 2b/3 Study Evaluating TG4010 in Combination With First-Line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC): Phase 2b Results
    Quoix, E.
    Losonczy, G.
    Forget, F.
    Chouaid, C.
    Papai, Z.
    Gervais, R.
    Ottensmeier, C.
    Szczesna, A.
    Kazarnowicz, A.
    Beck, J. T.
    Westeel, V.
    Vanderheyde, K.
    Lacoste, G.
    Bastien, B.
    Halluard, C.
    Marchand, S.
    Limacher, J. M.
    Lena, H.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S35 - S35
12345